Search results
Your search for ExmaQS returned no results
Showing 1 to 15 of 18 results for exams
Showing 1 to 15 of 18 results for exams
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations in people 12 years and older.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13
NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .
advisory committees, as well as a lay examiner for the RCOG part 3 membership exams. Stella O'Brien Biography Stella works with digital...
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .